|
Amgen: Denosumab Superior to Zometa in Advanced Breast Cancer Patients
Amgen’s osteoporosis candidate denosumab beat a potential rival in a clinical trial evaluating the products’ ability to delay complications related to bone metastases in advanced breast cancer patients.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives